FDA unveils “plausible mechanism” approval route for ultra-rare therapies; gene editing biotechs restructure amid capital constraints; medtech delivers strong quarters; EU AI regulations tighten device
Richard Pazdur’s CDER appointment signals regulatory evolution; China’s biotech resurgence opens cross-border opportunities; medtech financing hits $26.6B as capital markets normalize The life sciences sector
Trump administration brokers obesity drug pricing pact with Novo and Lilly; FDA approves daratumumab for earlier-line myeloma; geopolitical tensions ease for Illumina while BD navigates
Biotech opened the week navigating extreme regulatory volatility and clinical performance divergence. uniQure suffered a devastating 49% share collapse after the FDA reversed course on
Healthcare markets exploded with deal-making activity as November opened with a bang. Novartis dropped $12 billion to acquire Avidity Biosciences, Novo Nordisk and Pfizer escalated
The healthcare sector delivered a remarkable week of innovation, deal-making, and regulatory transformation. From the FDA’s groundbreaking National Priority Review program to over $6.4 billion
Markets experienced significant turbulence this week as banking sector concerns collided with healthcare earnings, policy developments, and robust deal-making activity. Here’s everything you need to
The healthcare sector is experiencing a profound transformation as industry giants restructure, pricing pressures intensify, and strategic acquisitions reshape the competitive landscape. Johnson & Johnson
The final week of September brought seismic shifts across the pharmaceutical and biotechnology sectors, with an $8 billion oncology acquisition, leadership changes at Big Pharma
After more than half a year without a sizable biotech IPO, LB Pharmaceuticals just raised $285 million in an upsized Nasdaq offering. For an industry
